orantinib has been researched along with Granulocytic Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Advani, AS | 1 |
| Albitar, M; Cherrington, JM; Giles, FJ; Smolich, BD; West, KA; Yuen, HA | 1 |
1 review(s) available for orantinib and Granulocytic Leukemia
| Article | Year |
|---|---|
C-kit as a target in the treatment of acute myelogenous leukemia.
Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Hematopoiesis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Piperazines; Propionates; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor | 2005 |
1 other study(ies) available for orantinib and Granulocytic Leukemia
| Article | Year |
|---|---|
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Topics: Angiogenesis Inhibitors; Apoptosis; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Humans; Indoles; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Oxindoles; Phosphorylation; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrroles; Stem Cell Factor; Tumor Cells, Cultured | 2001 |